Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials

M Eugenia-Toledo-Romaní, L Verdecia-Sánchez… - Vaccine, 2022 - Elsevier
Background SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …
被引用次数：41 相关文章
[PDF] ucv.ve

[PDF][PDF] Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme.

sostelemedicina.ucv.ve
Background SOBERANA 02 is a COVID-19 conjugate vaccine candidate based on SARS-
CoV-2 recombinant RBD conjugated to tetanus toxoid. SOBERANA Plus antigen is dimeric …

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme

M Eugenia-Toledo-Romani, L Verdecia-Sánchez… - medRxiv, 2021 - medrxiv.org
Background SOBERANA 02 is a COVID-19 conjugate vaccine candidate based on SARS-
CoV-2 recombinant RBD conjugated to tetanus toxoid. SOBERANA Plus antigen is dimeric …

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials

M Eugenia-Toledo-Romaní… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Background SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …
[HTML] europepmc.org

[HTML][HTML] Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme

M Eugenia-Toledo-Romani, L Verdecia-Sánchez… - 2021 - europepmc.org
Background SOBERANA 02 is a COVID-19 conjugate vaccine candidate based on SARS-
CoV-2 recombinant RBD conjugated to tetanus toxoid. SOBERANA Plus antigen is dimeric …

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA o2 in homologous or heterologous scheme: open label phase I and phase IIa clinical trials.

M Eugenia-Toledo-Romaní, L Verdecia-Sánchez… - 2022 - cabidigitallibrary.org
Background: SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …

Safety and Immunogenicity of Anti-SARS Cov-2 Vaccine SOBERANA 02 in Homologous or Heterologous Scheme

M Eugenia-Toledo-Romani, L Verdecia-Sánchez… - papers.ssrn.com
Background: SOBERANA 02 is a COVID-19 conjugate vaccine candidate based on SARS-
CoV-2 recombinant RBD conjugated to tetanus toxoid. SOBERANA Plus antigen is dimeric …
[PDF] finlay.edu.cu

[PDF][PDF] Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme.

finlay.edu.cu
Background SOBERANA 02 is a COVID-19 conjugate vaccine candidate based on SARS-
CoV-2 recombinant RBD conjugated to tetanus toxoid. SOBERANA Plus antigen is dimeric …
[HTML] nih.gov

[HTML][HTML] Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical …

M Eugenia-Toledo-Romaní, L Verdecia-Sánchez… - Vaccine, 2022 - ncbi.nlm.nih.gov
Background SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …
[HTML] sld.cu

[HTML][HTML] Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme

M Eugenia-Toledo-Romani, L Verdecia-Sánchez… - medRxiv, 2021 - covid19.sld.cu
Background SOBERANA 02 is a COVID-19 conjugate vaccine candidate based on SARS-
CoV-2 recombinant RBD conjugated to tetanus toxoid. SOBERANA Plus antigen is dimeric …